Please wait while the formulary information is being retrieved.
LYTGOBI (futibatinib)
- bile duct cancer with FGFR2 fusion or rearrangement
4 mg tablet
- by oral route once daily per package directions
Default screening record
- by oral route once daily per package directions
- 3 tablets (12 mg) by oral route once daily
- 4 tablets (16 mg) by oral route once daily
- 5 tablets (20 mg) by oral route once daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactation
Contraindicated
- Pregnancy
Severe
Moderate
- None
LYTGOBI (futibatinib)
- bile duct cancer with FGFR2 fusion or rearrangement
- Anemia
- Hypercalcemia
- Hyperphosphatemia
- Hyponatremia
- Lymphopenia
- Acute abdominal pain
- Alopecia
- Anorexia
- Arthralgia
- Constipation
- Diarrhea
- Dry eye
- Dry skin
- Dysgeusia
- Fatigue
- Hyperglycemia
- Musculoskeletal pain
- Nail disorders
- Nausea
- Palmar-plantar erythrodysesthesia
- Stomatitis
- Urinary tract infection
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- Hypophosphatemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Neutropenic disorder
- Retinal pigment epithelial detachment
- Thrombocytopenic disorder
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Calcification of vascular system
- Calcinosis cutis
- Calciphylaxis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Futibatinib
Safety and effectiveness not established in pediatrics.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatrics.
Futibatinib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology, developmental toxicity is possible
Contraindicated
Futibatinib
Insuff human data avail; avoid during tx and 1 week after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insuff human data avail; avoid during tx and 1 week after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Cholangiocarcinoma with FGFr2 fusion or rearrangement | |
| C22.1 | Intrahepatic bile duct carcinoma |
| C24.0 | Malignant neoplasm of extrahepatic bile duct |
| 0-9 | A-Z |
|---|---|
| C22.1 | Intrahepatic bile duct carcinoma |
| C24.0 | Malignant neoplasm of extrahepatic bile duct |
Formulary Reference Tool